Chongqing Pharscin Pharmaceutical Co.,Ltd. (002907.SZ) announced that the company has recently received approval notices issued by the Chongqing Drug Administration regarding the "Chemical Raw Material Drug Re-registration Approval Notice" for diammonium glycyrrhizinate chemical raw material and the "Drug Re-registration Approval Notice" for sodium ferulate injection. Diammonium glycyrrhizinate is a raw material drug used for producing diammonium glycyrrhizinate injection. Sodium ferulate injection is used as adjuvant therapy for ischemic cardiovascular and cerebrovascular diseases.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments